PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Scharl, S.* ; Zamboglou, C.* ; Strouthos, I.* ; Farolfi, A.* ; Serani, F.* ; Lanzafame, H.* ; Giuseppe Morganti, A.* ; Trapp, C.* ; Koerber, S.A.* ; Debus, J.* ; Peeken, J.C. ; Vogel, M.M. ; Vrachimis, A.* ; Spohn, S.K.B.* ; Ruf, J.* ; Grosu, A.L.* ; Ceci, F.* ; Fendler, W.P.* ; Bartenstein, P.* ; Kroeze, S.G.C.* ; Guckenberger, M.* ; Krafcsik, M.* ; Klopscheck, C.* ; Fanti, S.* ; Hruby, G.* ; Emmett, L.* ; Belka, C.* ; Stief, C.* ; Schmidt-Hegemann, N.S.* ; Henkenberens, C.* ; Mayer, B.* ; Miksch, J.* ; Shelan, M.* ; Aebersold, D.M.* ; Thamm, R.* ; Wiegel, T.*

Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study.

Radiother. Oncol. 184:109678 (2023)
Postprint DOI PMC
Open Access Green
BACKGROUND/PURPOSE: The present study aimed to assess whether SRT to the prostatic fossa should be initiated in a timely manner after detecting biochemical recurrence (BR) in patients with prostate cancer, when no correlate was identified with prostate-specific membrane antigen positron emission tomography (PSMA-PET). MATERIALS AND METHODS: This retrospective, multicenter analysis included 1222 patients referred for PSMA-PET after a radical prostatectomy due to BR. Exclusion criteria were: pathological lymph node metastases, prostate-specific antigen (PSA) persistence, distant or lymph node metastases, nodal irradiation, and androgen deprivation therapy (ADT). This led to a cohort of 341 patients. Biochemical progression-free survival (BPFS) was the primary study endpoint. RESULTS: The median follow-up was 28.0 months. The 3-year BPFS was 71.6% in PET-negative cases and 80.8% in locally PET-positive cases. This difference was significant in univariate (p = 0.019), but not multivariate analyses (p = 0.366, HR: 1.46, 95%CI: 0.64-3.32). The 3-year BPFS in PET-negative cases was significantly influenced by age (p = 0.005), initial pT3/4 (p < 0.001), pathology scores (ISUP) ≥ 3 (p = 0.026), and doses to fossa > 70 Gy (p = 0.027) in univariate analyses. In multivariate analyses, only age (HR: 1.096, 95%CI: 1.023-1.175, p = 0.009) and PSA-doubling time (HR: 0.339, 95%CI: 0.139-0.826, p = 0.017) remained significant. CONCLUSION: To our best knowledge, this study provided the largest SRT analysis in patients without ADT that were lymph node-negative on PSMA-PET. A multivariate analysis showed no significant difference in BPFS between locally PET-positive and PET-negative cases. These results supported the current EAU recommendation to initiate SRT in a timely manner after detecting BR in PET negative patients.
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
5.700
0.000
3
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Pet Negative ; Psma Pet-ct ; Prostate Cancer ; Salvage Radiotherapy
Language english
Publication Year 2023
HGF-reported in Year 2023
ISSN (print) / ISBN 0167-8140
e-ISSN 1879-0887
Journal Radiotherapy and Oncology
Quellenangaben Volume: 184, Issue: , Pages: , Article Number: 109678 Supplement: ,
Publisher Elsevier
Reviewing status Peer reviewed
Institute(s) Institute of Radiation Medicine (IRM)
POF-Topic(s) 30203 - Molecular Targets and Therapies
Research field(s) Radiation Sciences
PSP Element(s) G-501300-001
DOI 10.1016/j.radonc.2023.109678
Scopus ID 85159948886
PubMed ID 37146766
Erfassungsdatum 2023-10-06
[➜Report correction]